ALLMedicine™ Retinoblastoma Center
Research & Reviews 2,182 results
https://doi.org/10.1038/s41388-022-02394-8 10.3322/caac.21254 10.1001/jamaoncol.2017.3055 10.1053/j.gastro.2015.05.061 10.1158/0008-5472.CAN-20-0225 10.1002/hep.27198 10.1038/onc.2009.303 10.1084/jem.20110198 10.1016/j.molcel.2020.08.020 10.4161/cc.4.2.1485 10.1038/ng.2256 10.1038/onc.2009.282 10.1016/j.jhep.2015.03.023 10.1038/emm.2017.159 10.1101/gad.1200704 10.1016/j.celrep.2012.05.005 10.1128/MCB.24.7.2649-2661.2004 10.1074/jbc.M109.007997 10.1074/jbc.M605271200 10.1038/ncb1217 10.1128/MCB.25.24.10875-10894.2005 10.1038/sj.onc.1210814 10.4161/cc.24550 10.1016/j.bbaexp.2007.04.001 10.1002/emmm.201000107 10.1016/j.cell.2020.03.008 10.1016/j.ccr.2010.01.023 10.1159/000109185 10.1093/hmg/10.7.699 10.1016/j.molcel.2019.03.020 10.1016/j.trecan.2019.03.005 10.1016/j.cell.2017.04.001 10.1016/j.molcel.2005.05.012 10.1158/1541-7786.MCR-08-0176 10.1038/nature09264 10.1016/j.celrep.2018.12.080 10.1146/annurev-pathol-121808-102144 10.1007/s00216-007-1407-8
Oncogene Chand V, Liao X et. al.
Jun 28th, 2022 - Hepatocellular carcinoma (HCC) is one of the deadliest cancers. The retinoblastoma protein (RB1), a regulator of cell proliferation, is functionally inactivated in HCC by CYCLIN D/E-mediated phosphorylation. However, the mechanism of RB1-inactivat...
https://doi.org/10.1016/j.ophtha.2022.06.013
Ophthalmology Jansen RW, van der Heide S et. al.
Jun 26th, 2022 - To investigate prevalence and MRI phenotype of retinoblastoma-associated orbital cellulitis. Additionally, this study aimed to identify postlaminar optic nerve enhancement patterns differentiating between inflammation and tumor invasion. A monocen...
https://clinicaltrials.gov/ct2/show/NCT00342797
Jun 24th, 2022 - Retinoblastoma is a rare pediatric ocular tumor caused by germline and/or somatic mutations in the tumor suppressor gene RB1. Survivors of retinoblastoma, particularly those with the hereditary form of the disease (germline RB1 mutations) are high...
https://doi.org/10.1093/carcin/bgac057
Carcinogenesis Jaiswal N, Nandi D et. al.
Jun 24th, 2022 - The transforming properties of the high risk human papillomavirus (HPV) E7 oncoprotein are indispensable for driving the virus life cycle and pathogenesis. Besides inactivation of the retinoblastoma family of tumor suppressors as part of its oncog...
https://clinicaltrials.gov/ct2/show/NCT04941274
Jun 24th, 2022 - Background: Kaposi Sarcoma (KS) is a multicentric angioproliferative tumor, caused by Kaposi sarcoma-associated herpesvirus, that most frequently involves the skin, but may also involve lymph nodes, lungs, bone and gastrointestinal tract. It is mo...
Guidelines 1 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256324
Pediatric Radiology; de Graaf P, Göricke S et. al.
Aug 19th, 2011 - Retinoblastoma is the most common intraocular tumor in children. The diagnosis is usually established by the ophthalmologist on the basis of fundoscopy and US. Together with US, high-resolution MRI has emerged as an important imaging modality for ...
Drugs 19 results see all →
Clinicaltrials.gov 129 results
https://clinicaltrials.gov/ct2/show/NCT04941274
Jun 24th, 2022 - Background: Kaposi Sarcoma (KS) is a multicentric angioproliferative tumor, caused by Kaposi sarcoma-associated herpesvirus, that most frequently involves the skin, but may also involve lymph nodes, lungs, bone and gastrointestinal tract. It is mo...
https://clinicaltrials.gov/ct2/show/NCT00342797
Jun 24th, 2022 - Retinoblastoma is a rare pediatric ocular tumor caused by germline and/or somatic mutations in the tumor suppressor gene RB1. Survivors of retinoblastoma, particularly those with the hereditary form of the disease (germline RB1 mutations) are high...
https://clinicaltrials.gov/ct2/show/NCT01783535
Jun 10th, 2022 - Participants will be stratified into four main treatment groups, depending on whether retinoblastoma is present in one or both eyes and disease grouping [early or advanced, Reese-Ellsworth (R-E) group I-V, and International Classification A-E]. Ad...
https://clinicaltrials.gov/ct2/show/NCT03284268
Jun 8th, 2022 - Phase I study, single site, open label with dose escalation, for evaluate safety and the oncolitic Adenovirus VCN-01 activity in patients with refractory retinoblastoma.
https://clinicaltrials.gov/ct2/show/NCT02097134
Jun 7th, 2022 - PRIMARY OBJECTIVES: I. To study the feasibility of delivering melphalan directly into the ophthalmic artery in children with newly diagnosed unilateral group D retinoblastoma, who would otherwise be considered for enucleation. SECONDARY OBJECTIVES...
News 89 results
https://www.onclive.com/view/net-guides-childhood-tumors
Mar 15th, 2022 - //THE ONLINE ONCOLOGIST™ American Society of Pediatric Hematology/Oncology The American Society of Pediatric Hematology/Oncology (ASPHO) is a multidisciplinary organization that works to promote the care of children and adolescents with blo...
https://www.onclive.com/view/brachytherapy-represents-a-potential-strategy-in-aya-patients-with-rhabdomyosarcoma
Feb 9th, 2022 - Although brachytherapy (BT) is rarely utilized as a treatment for pediatric and adolescent/young adult (AYA) patients in the United States, AYA patients with rhabdomyosarcoma (RMS) treated with BT had favorable survival outcomes, according to find...
https://www.onclive.com/view/trilaciclib-prior-to-myelosuppressive-chemo-reduces-need-for-supportive-care-in-small-cell-lung-cancer
Oct 6th, 2021 - Trilaciclib administered prior to chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC) helped to reduce chemotherapy-induced myelosuppression and limit the need for granulocyte colony-stimulating factors (G-CSF), erythrop...
https://www.medscape.com/viewarticle/957441
Aug 27th, 2021 - Josie Rock was taking pictures of her 3-month-old son Asher when the lighting in the room suddenly dimmed, initiating the flash on her iPhone. Asher's eyes opened wide, but instead of his pupils glowing red, as they normally do when a flash is use...
https://www.onclive.com/view/fda-approval-of-ribociclib-for-metastatic-breast-cancer
Apr 2nd, 2021 - Transcript:Adam M. Brufsky, MD, PhD: Hello, and thank you for joining us in this OncLive Peer Exchange® titled Questions and Controversies in Treating Breast Cancer. Evidence-based management of breast cancer has become increasingly complex owing ...
